

Clemens H M Kocken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4686023/publications.pdf>

Version: 2024-02-01

40
papers

2,318
citations

361413

20
h-index

289244

40
g-index

42
all docs

42
docs citations

42
times ranked

3229
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Plasmodium PI(4)K to eliminate malaria. <i>Nature</i> , 2013, 504, 248-253.	27.8	377
2	Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques. <i>Nature Medicine</i> , 2019, 25, 255-262.	30.7	227
3	Antimalarial efficacy of MMV390048, an inhibitor of <i>Plasmodium</i> phosphatidylinositol 4-kinase. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	204
4	Quinolone-3-Diarylethers: A New Class of Antimalarial Drug. <i>Science Translational Medicine</i> , 2013, 5, 177ra37.	12.4	187
5	High-Level Expression of the Malaria Blood-Stage Vaccine Candidate <i>Plasmodium falciparum</i> Apical Membrane Antigen 1 and Induction of Antibodies That Inhibit Erythrocyte Invasion. <i>Infection and Immunity</i> , 2002, 70, 4471-4476.	2.2	181
6	Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. <i>Nature Medicine</i> , 2014, 20, 307-312.	30.7	160
7	A Diversity-Covering Approach to Immunization with <i>Plasmodium falciparum</i> Apical Membrane Antigen 1 Induces Broader Allelic Recognition and Growth Inhibition Responses in Rabbits. <i>Infection and Immunity</i> , 2008, 76, 2660-2670.	2.2	107
8	High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria. <i>ACS Infectious Diseases</i> , 2016, 2, 281-293.	3.8	84
9	<i>Plasmodium knowlesi</i> Provides a Rapid In Vitro and In Vivo Transfection System That Enables Double-Crossover Gene Knockout Studies. <i>Infection and Immunity</i> , 2002, 70, 655-660.	2.2	81
10	Variable BCG efficacy in rhesus populations: Pulmonary BCG provides protection where standard intra-dermal vaccination fails. <i>Tuberculosis</i> , 2017, 104, 46-57.	1.9	80
11	A comparative transcriptomic analysis of replicating and dormant liver stages of the relapsing malaria parasite <i>Plasmodium cynomolgi</i> . <i>ELife</i> , 2017, 6, .	6.0	56
12	Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid. <i>European Journal of Immunology</i> , 1998, 28, 1225-1232.	2.9	53
13	A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. <i>Nature Communications</i> , 2017, 8, 15159.	12.8	51
14	PI4 Kinase Is a Prophylactic but Not Radical Curative Target in <i>Plasmodium vivax</i> -Type Malaria Parasites. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2858-2863.	3.2	45
15	Robust continuous in vitro culture of the <i>Plasmodium cynomolgi</i> erythrocytic stages. <i>Nature Communications</i> , 2019, 10, 3635.	12.8	39
16	A dual fluorescent <i>Plasmodium cynomolgi</i> reporter line reveals in vitro malaria hypnozoite reactivation. <i>Communications Biology</i> , 2020, 3, 7.	4.4	36
17	Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	33
18	Lead Optimization of Imidazopyrazines: A New Class of Antimalarial with Activity on <i>Plasmodium</i> Liver Stages. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 947-950.	2.8	30

#	ARTICLE	IF	CITATIONS
19	Disparate Tuberculosis Disease Development in Macaque Species Is Associated With Innate Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 2479.	4.8	27
20	Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. <i>Cell Reports Medicine</i> , 2021, 2, 100187.	6.5	26
21	<i>Plasmodium knowlesi</i> : a relevant, versatile experimental malaria model. <i>Parasitology</i> , 2018, 145, 56-70.	1.5	23
22	<i>Plasmodium vivax</i> : In vitro susceptibility of blood stages to synthetic trioxolane compounds and the diamidine DB75. <i>Experimental Parasitology</i> , 2006, 113, 197-200.	1.2	22
23	Variations in the quality of malaria-specific antibodies with transmission intensity in a seasonal malaria transmission area of Northern Ghana. <i>PLoS ONE</i> , 2017, 12, e0185303.	2.5	17
24	From marginal to essential: the golden thread between nutrient sensing, medium composition and <i>Plasmodium vivax</i> maturation in in vitro culture. <i>Malaria Journal</i> , 2019, 18, 344.	2.3	17
25	Transgenic <i>Plasmodium knowlesi</i> : relieving a bottleneck in malaria research?. <i>Trends in Parasitology</i> , 2009, 25, 370-374.	3.3	16
26	Crystal Structure of <i>Plasmodium knowlesi</i> Apical Membrane Antigen 1 and Its Complex with an Invasion-Inhibitory Monoclonal Antibody. <i>PLoS ONE</i> , 2015, 10, e0123567.	2.5	16
27	Low Levels of Polymorphisms and No Evidence for Diversifying Selection on the <i>Plasmodium knowlesi</i> Apical Membrane Antigen 1 Gene. <i>PLoS ONE</i> , 2015, 10, e0124400.	2.5	15
28	Workshop report: Malaria vaccine development in Europe—preparing for the future. <i>Vaccine</i> , 2015, 33, 6137-6144.	3.8	15
29	Modeling Relapsing Malaria: Emerging Technologies to Study Parasite-Host Interactions in the Liver. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 606033.	3.9	11
30	Statistical Model To Evaluate In Vivo Activities of Antimalarial Drugs in a <i>Plasmodium cynomolgi</i> -Macaque Model for <i>Plasmodium vivax</i> Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 421-427.	3.2	10
31	Antibody Responses to a Novel <i>Plasmodium falciparum</i> Merozoite Surface Protein Vaccine Correlate with Protection against Experimental Malaria Infection in Aotus Monkeys. <i>PLoS ONE</i> , 2014, 9, e83704.	2.5	10
32	Parasite-Host Interaction and Pathophysiology Studies of the Human Relapsing Malaria <i>Plasmodium vivax</i> and <i>Plasmodium ovale</i> Infections in Non-Human Primates. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 614122.	3.9	9
33	Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation. <i>BMC Immunology</i> , 2018, 19, 6.	2.2	8
34	Evaluation of Chimpanzee Adenovirus and MVA Expressing TRAP and CSP from <i>Plasmodium cynomolgi</i> to Prevent Malaria Relapse in Nonhuman Primates. <i>Vaccines</i> , 2020, 8, 363.	4.4	7
35	Dual-Luciferase-Based Fast and Sensitive Detection of Malaria Hypnozoites for the Discovery of Antirelapse Compounds. <i>Analytical Chemistry</i> , 2020, 92, 6667-6675.	6.5	7
36	Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation. <i>PLoS ONE</i> , 2016, 11, e0164053.	2.5	7

#	ARTICLE	IF	CITATIONS
37	Transformed <i>Toxoplasma gondii</i> Tachyzoites Expressing the Circumsporozoite Protein of <i>Plasmodium knowlesi</i> Elicit a Specific Immune Response in Rhesus Monkeys. <i>Infection and Immunity</i> , 1999, 67, 1677-1682.	2.2	6
38	Identification of adjuvants for clinical trials performed with <i>Plasmodium falciparum</i> AMA1 in rabbits. <i>BMC Immunology</i> , 2019, 20, 25.	2.2	4
39	A Bacterially-Expressed Recombinant Envelope Protein from Usutu Virus Induces Neutralizing Antibodies in Rabbits. <i>Vaccines</i> , 2021, 9, 157.	4.4	3
40	Metabolic, Pharmacokinetic, and Activity Profile of the Liver Stage Antimalarial (RC-12). <i>ACS Omega</i> , 2022, 7, 12401-12411.	3.5	1